All Content

Subpopulation of Breast Cancer Patients Most Likely to Respond to Palbociclib

This slide show features some of the highlights from the 105th Annual Meeting of the American Association for Cancer Research (AACR), including a breast cancer trial of .

A 48-year-old woman presents with a soft-tissue nodular lesion in the right forearm. Surgical resection of the lesion is performed. What is your diagnosis?

Patients with localized prostate cancer treated with primary androgen deprivation therapy (ADT) without radiation therapy or surgery derived no survival benefit, according to the results of a large study.

A new pilot study demonstrates the ability of a blood-based test to detect metastatic breast cancer recurrence with high sensitivity and specificity.

This slide show includes highlights from the 2014 Society of Gynecologic Oncology annual meeting, including one study showing bariatric surgery could lower the risk of uterine cancer, and another that found a PARP inhibitor active in BRCA-positive ovarian cancer.

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

Using both clinical and molecular markers, researchers have created a simple prognostic index for patients with cytogenetically normal acute myeloid leukemia (AML).

The addition of gemcitabine to a cisplatin- and ifosfamide-containing drug regimen resulted in a complete response rate of greater than 50% in patients with relapsed metastatic germ cell tumors, results of a phase II study indicated.

Although uncommon in women less than 40 years old, breast cancer in younger women may have unique biologic and treatment implications. The purpose of this study was to evaluate treatment of breast cancer in young women with respect to previously established clinical predictors of local therapy choice.

There are over 3.0 million cases of nonmelanoma skin cancer (NMSC) diagnosed each year in the United States. Multiple treatment options exist for the treatment of these patients. We describe the outcomes of patients treated at a large private dermatology practice with electronic brachytherapy (eBx) who had a minimum follow-up duration of 1 year.


Please Wait 20 seconds or click here to close